Geriatric nutritional risk index is not an independent predictor in patients with diffuse large B-cell lymphoma

被引:1
|
作者
Li, Zhongqi [1 ,2 ]
Guo, Qi [3 ]
Wei, Juying [1 ,4 ]
Jin, Jie [1 ,4 ]
Wang, Jinghan [1 ,4 ]
机构
[1] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Hematol, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Surg Oncol, Hangzhou, Zhejiang, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Nephrol, Hangzhou, Zhejiang, Peoples R China
[4] Zhejiang Univ, Zhejiang Prov Key Lab Hematopoiet Malignancy, Hangzhou, Zhejiang, Peoples R China
基金
中国国家自然科学基金;
关键词
lymphoma; nutritional risk; predictor; R-CHOP; PROGNOSTIC-SIGNIFICANCE; CANCER; METAANALYSIS; MORTALITY; IPI;
D O I
10.3233/CBM-170754
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: The prognostic value of geriatric nutritional risk index (GNRI) for diffuse large B-cell lymphoma (DLBCL) treated in the rituximab era was not clear. OBJECTIVE: To investigate the prognostic impact of GNRI in patients with DLBCL in our hospital. METHODS: DLBCL patients were recruited and classified into two groups with and without malnutrition based on GNRI. Clinical features, concentration of T-helper cell type (Th1/Th2/Th17) cytokine profiles and overall survival were compared between these two groups. RESULTS: One hundred and five (39%) out of 267 patients were classified into malnutrition group. Patients with malnutrition had lower levels of albumin and hemoglobin, but older age, higher lactate dehydroxygenase (LDH) level, higher frequencies of advanced stage, poor performance status, B symptoms and extranodal involvement, higher scores of NCCN-IPI and higher level of INF-gamma. Moreover, patients with malnutrition had poor overall survival in univariate analyses. But these significances did not stand after stratified analyses by NCCN-IPI, or in the context of NCCN-IPI in the multivariate analyses. CONCLUSIONS: GNRI is not an independent predictor for DLBCL patients.
引用
收藏
页码:813 / 820
页数:8
相关论文
共 50 条
  • [41] Diffuse large B-cell lymphoma
    Fuchs, David
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2019, 12 (01) : 7 - 11
  • [42] Diffuse large B-cell lymphoma
    Salles, G.
    EJC SUPPLEMENTS, 2010, 8 (04): : 8 - 9
  • [43] Diffuse large B-cell lymphoma
    Ng, Andrea K.
    SEMINARS IN RADIATION ONCOLOGY, 2007, 17 (03) : 169 - 175
  • [44] Diffuse large B-cell lymphoma
    Martelli, Maurizio
    Ferreri, Andres J. M.
    Agostinelli, Claudio
    Di Rocco, Alice
    Pfreundschuh, Michael
    Pileri, Stefano A.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2013, 87 (02) : 146 - 171
  • [45] Diffuse large B-cell lymphoma
    Decool, Gauthier
    Theves, Floriane
    HEMATOLOGIE, 2018, 24 : 35 - 40
  • [46] Diffuse Large B-Cell Lymphoma
    Lang, Raynell
    Gill, M. John
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (23): : 2261 - 2262
  • [47] Diffuse Large B-Cell Lymphoma
    Friedberg, Jonathan W.
    Fisher, Richard I.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2008, 22 (05) : 941 - +
  • [48] Diffuse large B-cell lymphoma
    Shahi, Parham Khosravi
    Manga, Gumersindo Perez
    MEDICINA CLINICA, 2006, 127 (01): : 17 - 21
  • [49] The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era
    T Kobayashi
    J Kuroda
    I Yokota
    K Tanba
    T Fujino
    S Kuwahara
    R Isa
    J Yamaguchi
    E Kawata
    T Akaogi
    H Uchiyama
    H Kaneko
    N Uoshima
    Y Kobayashi
    S Teramukai
    M Taniwaki
    Blood Cancer Journal, 2016, 6 : e383 - e383
  • [50] The Kyoto Prognostic Index for Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era
    Kobayashi, Tsutomu
    Kuroda, Junya
    Yokota, Isao
    Tanba, Kazuna
    Taki, Tomohiko
    Fujino, Takahiro
    Kuwahara, Saeko
    Isa, Reiko
    Yamaguchi, Junko
    Kawata, Eri
    Akaogi, Teruaki
    Uchiyama, Hitoji
    Kaneko, Hiroto
    Uoshima, Nobuhiko
    Kobayashi, Yutaka
    Teramukai, Satoshi
    Taniwaki, Masafumi
    BLOOD, 2015, 126 (23)